Palatin Technologies (PTN) Misses Q2 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. FISV
10. CVS

Go back to Palatin Technologies (PTN) Misses Q2 EPS by 1c

Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2016 Results; Teleconference and Webcast to be held on February 16, 2016

February 16, 2016 7:30 AM EST

CRANBURY, N.J., Feb. 16, 2016 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its second quarter ended December 31, 2015. 

Recent Highlights

Bremelanotide development for Female Sexual Dysfunction (FSD): Palatin's two Phase 3 clinical trials for the treatment of FSD initiated in December 2014 and January 2015 are progressing as planned and meeting target objectives. Patient enrollment was completed in the... More